{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:40:33Z","timestamp":1782981633788,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,5,31]],"date-time":"2012-05-31T00:00:00Z","timestamp":1338422400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2407-12-210","type":"journal-article","created":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T13:14:50Z","timestamp":1352121290000},"source":"Crossref","is-referenced-by-count":9,"title":["Has the time to come leave the \u201cwatch-and-wait\u201d strategy in newly diagnosed asymptomatic follicular lymphoma patients?"],"prefix":"10.1186","volume":"12","author":[{"given":"Antonio","family":"Rueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximino","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"P\u00e9rez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Medina-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,31]]},"reference":[{"key":"3339_CR1","first-page":"220","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"NL Harris","year":"2008","unstructured":"Harris NL, Swerdlow SH, Jaffe ES, et al: Follicular lymphoma. WHO classification of tumours of haematopoietic and lymphoid tissues. Edited by: Swerdlow SH, Campo E, Harris NL, Es J, Pireli SA, Stein H, Thiele J, Vardoman JW. 2008, Lyon: IARC, 220-226."},{"key":"3339_CR2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/annonc\/mdp148","volume":"4","author":"M Dreyling","year":"2009","unstructured":"Dreyling M: Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009, 4: 119-120.","journal-title":"Ann Oncol"},{"key":"3339_CR3","volume-title":"Cancer Incidence in Five Continents, Volume IX","year":"2009","unstructured":"Cancer Incidence in Five Continents, Volume IX. Edited by: Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P. 2009, Lyon, France: International Agency for Research on Cancer Scientific Publications n\u00b0 160"},{"key":"3339_CR4","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1056\/NEJM198806233182502","volume":"318","author":"BY Ngan","year":"1988","unstructured":"Ngan BY, Chen-Levy Z, Weiss LM, et al: Expression in non-Hodgkin\u00b4s lymphoma of the bcl-2 protein associated with the t(14,18) chromosomal translocation. N Engl J Med. 1988, 318: 1638-1644. 10.1056\/NEJM198806233182502.","journal-title":"N Engl J Med"},{"key":"3339_CR5","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.humpath.2005.12.005","volume":"37","author":"AG Bosga-Bouwer","year":"2006","unstructured":"Bosga-Bouwer AG, van der Berg A, Haralambieva E, et al: Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma?. Hum Pathol. 2006, 37: 528-533. 10.1016\/j.humpath.2005.12.005.","journal-title":"Hum Pathol"},{"key":"3339_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1365-2141.2011.08596.x","volume":"153","author":"C Fern\u00e1ndez de Larrea","year":"2011","unstructured":"Fern\u00e1ndez de Larrea C, Mart\u00ednez-Pozo A, Mercadal S, et al: Initial features and outcome of cutaneous and non-cutaneous primary extranodal follicular lymphoma. Br J Haematol. 2011, 153: 334-10.1111\/j.1365-2141.2011.08596.x.","journal-title":"Br J Haematol"},{"key":"3339_CR7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood. 2004, 104: 783-789.","journal-title":"Blood"},{"key":"3339_CR8","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, et al: Follicular Lymphoma International Prognostic Index 2: A new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. J Clin Oncol. 2009, 27: 4555-4562. 10.1200\/JCO.2008.21.3991.","journal-title":"J Clin Oncol"},{"key":"3339_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1200\/jco.2003.05.128","volume":"21","author":"BS Peterson","year":"2003","unstructured":"Peterson BS, Petroni GR, Frizera G, et al: Prolonged single-sgent versus combination chemotherapy in indolent follicular lymphomas: A study of the Cancer and Leukemia Group B. J Clin Oncol. 2003, 21: 5-15. 10.1200\/jco.2003.05.128.","journal-title":"J Clin Oncol"},{"key":"3339_CR10","first-page":"75","volume":"20","author":"SJ Horning","year":"1993","unstructured":"Horning SJ: Natural history of and therapy for the indolent non-Hodgkin\u00b4s lymphomas. Semin Oncol. 1993, 20: 75-88.","journal-title":"Semin Oncol"},{"key":"3339_CR11","doi-asserted-by":"publisher","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher RI, LeBlanc M, Press OW, et al: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005, 23: 8447-8452. 10.1200\/JCO.2005.03.1674.","journal-title":"J Clin Oncol"},{"key":"3339_CR12","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","volume":"22","author":"MS Czuczman","year":"2004","unstructured":"Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-L\u00f3pez AJ: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004, 22: 4711-4716. 10.1200\/JCO.2004.04.020.","journal-title":"J Clin Oncol"},{"key":"3339_CR13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/asheducation-2006.1.303","volume":"1","author":"MS Czuczman","year":"2006","unstructured":"Czuczman MS: Controversies in follicular lymphoma: \u201cWho, What, When, Where, and Why?\u201d (Not necessarily in that order). Hematology Am Soc Hematol Educ Program. 2006, 1: 303-310.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3339_CR14","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, et al: Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997, 15: 1110-1117.","journal-title":"J Clin Oncol"},{"key":"3339_CR15","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","volume":"16","author":"P Solal-Celigny","year":"1998","unstructured":"Solal-Celigny P, Lepage E, Brousse N, et al: Doxorubicin-containing regimen with o without interferon alfa-2b for advanced follicular lymphoma: final analysis of survival and toxicity in the Groupe d\u00c9tude des Lymphomes Folliculaires 86 trial. J Clin Oncol. 1998, 16: 2332-2338.","journal-title":"J Clin Oncol"},{"key":"3339_CR16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.6004\/jnccn.2011.0046","volume":"9","author":"AD Zelenetz","year":"2011","unstructured":"Zelenetz AD, Abramson JS, Advani RH, et al: Non-Hodgkin\u00b4s lymphomas. J Natl Compr Canc Netw. 2011, 9: 484-560.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2 Suppl 2","key":"3339_CR17","first-page":"11","volume":"25","author":"RC Young","year":"1988","unstructured":"Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT: The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988, 25 (2 Suppl 2): 11-16.","journal-title":"Semin Hematol"},{"key":"3339_CR18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, et al: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003, 362: 516-522. 10.1016\/S0140-6736(03)14110-4.","journal-title":"Lancet"},{"key":"3339_CR19","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/1097-0142(19861015)58:8<1596::AID-CNCR2820580803>3.0.CO;2-G","volume":"58","author":"P McLaughlin","year":"1986","unstructured":"McLaughlin P, Fuller LM, Velasquez WS, et al: Stage I-II follicular lymphoma. Treatment results for 76 patients. Cancer. 1986, 58: 1596-1602. 10.1002\/1097-0142(19861015)58:8<1596::AID-CNCR2820580803>3.0.CO;2-G.","journal-title":"Cancer"},{"key":"3339_CR20","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","volume":"64","author":"BA Guadagnolo","year":"2006","unstructured":"Guadagnolo BA, Li S, Neuberg D, et al: Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2006, 64: 928-934. 10.1016\/j.ijrobp.2005.08.010.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3339_CR21","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","volume":"22","author":"R Advani","year":"2004","unstructured":"Advani R, Rosenberg SA, Horning SJ: Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004, 22: 1454-1459. 10.1200\/JCO.2004.10.086.","journal-title":"J Clin Oncol"},{"key":"3339_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/oxfordjournals.annonc.a010720","volume":"7","author":"P Soubeyran","year":"1996","unstructured":"Soubeyran P, Eghbali H, Trojani M, et al: Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center. Ann Oncol. 1996, 7: 713-718. 10.1093\/oxfordjournals.annonc.a010720.","journal-title":"Ann Oncol"},{"key":"3339_CR23","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","volume":"25","author":"S Montoto","year":"2007","unstructured":"Montoto S, Davies AJ, Matthews J, et al: Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007, 25: 2426-2433. 10.1200\/JCO.2006.09.3260.","journal-title":"J Clin Oncol"},{"key":"3339_CR24","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S, et al: Immunotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007, 99: 706-714. 10.1093\/jnci\/djk152.","journal-title":"J Natl Cancer Inst"},{"key":"3339_CR25","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MH Van Oers","year":"2010","unstructured":"Van Oers MH, Van Glabbeke M, Giurgea L, et al: Rituximab maintenance treatment of relapsed\/resitant follicular non-Hoddkin\u00b4s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010, 28: 2853-2858. 10.1200\/JCO.2009.26.5827.","journal-title":"J Clin Oncol"},{"key":"3339_CR26","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005, 105: 1417-23. 10.1182\/blood-2004-08-3175.","journal-title":"Blood"},{"key":"3339_CR27","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008, 26: 4579-4586. 10.1200\/JCO.2007.13.5376.","journal-title":"J Clin Oncol"},{"key":"3339_CR28","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005, 106: 3725-3732. 10.1182\/blood-2005-01-0016.","journal-title":"Blood"},{"key":"3339_CR29","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology study. J Clin Oncol. 2007, 25: 1986-1992. 10.1200\/JCO.2006.06.4618.","journal-title":"J Clin Oncol"},{"key":"3339_CR30","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","volume":"112","author":"G Salles","year":"2008","unstructured":"Salles G, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008, 112: 4824-4831. 10.1182\/blood-2008-04-153189.","journal-title":"Blood"},{"key":"3339_CR31","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","volume":"20","author":"JD Hainsworth","year":"2002","unstructured":"Hainsworth JD, Litchy S, Burris HA, et al: Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol. 2002, 20: 4261-4267. 10.1200\/JCO.2002.08.674.","journal-title":"J Clin Oncol"},{"key":"3339_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1182\/blood.V97.1.101","volume":"97","author":"P Colombat","year":"2001","unstructured":"Colombat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001, 97: 101-106. 10.1182\/blood.V97.1.101.","journal-title":"Blood"},{"key":"3339_CR33","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","volume":"23","author":"T Witzig","year":"2005","unstructured":"Witzig T, Vukov AM, Habermann TH, et al: Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin\u2019s lymphoma: a phase II Trial in the North Central Cancer Treatment Group. J Clin Oncol. 2005, 23: 1103-1108. 10.1200\/JCO.2005.12.052.","journal-title":"J Clin Oncol"},{"key":"3339_CR34","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004, 103: 4416-4423. 10.1182\/blood-2003-10-3411.","journal-title":"Blood"},{"key":"3339_CR35","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","volume":"28","author":"G Martinelli","year":"2010","unstructured":"Martinelli G, Schmitz SF, Utiger U, et al: Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98. J Clin Oncol. 2010, 28: 4480-4484. 10.1200\/JCO.2010.28.4786.","journal-title":"J Clin Oncol"},{"key":"3339_CR36","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"MS Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J, et al: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005, 352: 441-449. 10.1056\/NEJMoa041511.","journal-title":"N Engl J Med"},{"key":"3339_CR37","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KH Robinson","year":"2008","unstructured":"Robinson KH, Williams ME, van der Jagt RH, et al: Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-Cell and mantle cell Non-Hodgkin\u2019s Lymphoma. J Clin Oncol. 2008, 26: 4473-4479. 10.1200\/JCO.2008.17.0001.","journal-title":"J Clin Oncol"},{"key":"3339_CR38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood.V114.22.405.405","volume":"114","author":"MJ Rummel","year":"2009","unstructured":"Rummel MJ, Norbert Niederle N, Maschmeyer G, et al: Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 2009, 114: 168-abstr 405","journal-title":"Blood"},{"key":"3339_CR39","doi-asserted-by":"crossref","first-page":"abstract 6","DOI":"10.1182\/blood.V116.21.6.6","volume":"116","author":"KM Ardeshna","year":"2010","unstructured":"Ardeshna KM, Smith P, Qian W, et al: An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis. Blood. 2010, 116: abstract 6-ASH Annual Meeting Abstracts","journal-title":"Blood"},{"issue":"Suppl 4","key":"3339_CR40","first-page":"Abstract 019","volume":"22","author":"KM Ardeshna","year":"2011","unstructured":"Ardeshna KM, Qian W, Stephens R, et al: Preliminary results of quality of life (QoL) analyses from the Intergroup Phase III randomised trial of rituximab vs a watch and wait approach in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma. Ann Oncol. 2011, 22 (Suppl 4): Abstract 019-","journal-title":"Ann Oncol"},{"key":"3339_CR41","doi-asserted-by":"publisher","first-page":"abstract 6","DOI":"10.1182\/blood-2011-05-352567","volume":"118","author":"BS Kahl","year":"2011","unstructured":"Kahl BS, Hong F, Williams ME, et al: Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood. 2011, 118: abstract 6-ASH Annual Meeting Abstract","journal-title":"Blood"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-12-210\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T14:48:49Z","timestamp":1594824529000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-12-210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,31]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["3339"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-12-210","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,31]]},"article-number":"210"}}